A5010378038- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Epigenetics and DNA Methylation
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Pancreatic and Hepatic Oncology Research
- Head and Neck Cancer Studies
- Statistical Methods in Clinical Trials
- Ferroptosis and cancer prognosis
- Single-cell and spatial transcriptomics
- Peptidase Inhibition and Analysis
Austin Health
2016-2025
Austin Hospital
2016-2025
Olivia Newton-John Cancer Wellness & Research Centre
2016-2025
La Trobe University
2016-2025
Baylor College of Medicine
2014-2025
The University of Melbourne
2008-2025
Huzhou University
2025
Guangxi Academy of Fishery Sciences
2020-2024
Chongqing Medical University
2020-2024
Children's Hospital of Chongqing Medical University
2020-2024
Recent molecular classification of glioblastoma (GBM) has shown that patients with a mesenchymal (MES) gene expression signature exhibit poor overall survival and treatment resistance. Using regulatory network analysis available microarray data sets GBM, including The Cancer Genome Atlas (TCGA), we identified the transcriptional coactivator PDZ-binding motif (TAZ), to be highly associated MES network. TAZ was lower in proneural (PN) GBMs lower-grade gliomas, which correlated CpG island...
Abstract Background Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised a monoclonal antibody that binds activated EGFR (overexpressed wild-type EGFRvIII-mutant) linked to microtubule-inhibitor toxin in EGFR-amp GBMs. Methods In this phase III trial, adults with centrally confirmed,...
Recent studies have shown the importance of dynamic tumor microenvironment (TME) in high-grade gliomas (HGGs). In particular, myeloid cells are known to mediate immunosuppression glioma; however, it is still unclear if play a role low-grade glioma (LGG) malignant progression. Here, we investigate cellular heterogeneity TME using single-cell RNA sequencing murine model that recapitulates progression LGG HGG. LGGs show increased infiltrating CD4
Abstract Purpose: Tumor antigen-loaded dendritic cells show promise for cancer immunotherapy. This phase I study evaluated immunization with autologous pulsed mannan-MUC1 fusion protein (MFP) to treat patients advanced malignancy. Experimental Design: Eligible had adenocarcinoma expressing MUC1, were of performance status 0 1, no autoimmune disease. Patients underwent leukapheresis generate by culture ex vivo granulocyte macrophage colony-stimulating factor and interleukin 4 5 days....
Neurolymphomatosis (NL) is an uncommon syndrome of peripheral or cranial nerve root dysfunction secondary to infiltration by B-cell non-Hodgkin's lymphoma (NHL). A high index suspicion required as presenting symptoms are varied, conventional radiology has only modest sensitivity, and pathological diagnosis often difficult. Treatment with chemotherapy alone objective response rate 82%, although long-term outcomes highly variable. This case series describes in four patients whose management...
BackgroundThe immune therapeutic potential of microRNAs (miRNAs) in the context tumor-mediated suppression has not been previously described for monocyte-derived glioma-associated macrophages, which are largest infiltrating cell population glioblastomas and facilitate gliomagenesis.